News | November 20, 2008

Biomarkers Connect Pathway Signaling to Adverse Outcome in Brain Tumor Patients

November 20, 2008 – In the most comprehensive correlative analysis of biomarker data for glioblastoma multiforme patients treated with an epidermal growth factor receptor (EGFR) inhibitor, RTOG investigators identified a subset of patients who had significantly shorter survival times when treated with the anti-EFGR therapy according to new research from the Radiation Therapy Oncology Group (RTOG) presented at the Society for Neuro-Oncology 13th Annual Meeting in Lake Las Vegas, NV.

“Although RTOG investigators did not find a survival advantage when they added gefitinib, an EGFR inhibitor, to standard radiotherapy for glioblastoma multiforme patients, we have identified a subset of patients that fare significantly worse,” said lead author Arnab Chakravarti, M.D., of Massachusetts General Hospital, MA. “We hope that an analysis of a larger panel of markers will identify subsets of patients who respond to EGFR therapy, but each result adds to our understanding of this disease.”

The initial analysis of RTOG 0211, a phase I/II trial of gefitinib given during and for 18 months after standard radiotherapy for glioblastoma multiforme (GBM) patients, showed that gefitinib was generally well tolerated but that survival times were not significantly improved compared to historical controls. A secondary analysis of study data is attempting to identify molecular subgroups of GBM patients that are likely to benefit from anti-EGFR therapies. Tissue microarrays generated from blocks prospectively collected on 74 of the 148 patients entered on RTOG 0211 were used to analyze the predictive values of 12 molecules integral to EGFR signaling. Using this molecular data, a multivariate risk model was developed using both clinical and molecular data that appears to identify distinct populations of GBM patients who may derive an overall survival benefit from the addition of Gefitinib to radiation in the upfront setting. This data strongly highlights activation of the phosphoinositol 3-kinase (PI3K) pathway at various junctions as a major resistance mechanism to gefitinib in GBMs. The results of this study may not only aid clinicians in selecting appropriate GBM patients for anti-EGFR therapies, but may also shed light into the basic mechanisms leading to treatment resistance in these most devastating tumors.

“RTOG biomarker investigations are providing new insights into the complex mechanisms of tumor growth and drug resistance,” said Walter J. Curran, Jr., the RTOG Group Chair, and the Lawrence W. Davis professor and chair of the Department of Radiation Oncology in the Emory School of Medicine and chief medical officer of the Emory Winship Cancer Institute. “The group’s repository of biospecimen material collected on thousands of brain tumor patients at hundreds of North American facilities is an invaluable resource for RTOG and the scientific community.”

For more information:

Related Content

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Overlay Init